Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016

  • ID: 3746951
  • Report
  • Region: Global
  • 65 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • Mallinckrodt Plc
  • Obexia AG
  • Pfizer Inc.
  • Retrophin Inc.
  • MORE
Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016

Summary

‘Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016’, provides in depth analysis on Melanocortin Receptor 4 (MC4-R or MC4R) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanocortin Receptor 4 (MC4-R or MC4R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4-R or MC4R)
- The report reviews Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4-R or MC4R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4-R or MC4R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • Mallinckrodt Plc
  • Obexia AG
  • Pfizer Inc.
  • Retrophin Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Melanocortin Receptor 4 (MC4-R or MC4R) Overview

Therapeutics Development

Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Stage of Development

Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Therapy Area

Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Indication

Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Unknown Stage Products

Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Companies

Melanocortin Receptor 4 (MC4-R or MC4R) - Products under Development by Universities/Institutes

Melanocortin Receptor 4 (MC4-R or MC4R) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocortin Receptor 4 (MC4-R or MC4R) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Mallinckrodt Plc

Obexia AG

Palatin Technologies, Inc.

Pfizer Inc.

Retrophin Inc.

Rhythm Pharmaceuticals, Inc.

Melanocortin Receptor 4 (MC4-R or MC4R) - Drug Profiles

(liraglutide + setmelanotide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cosyntropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OBX-1201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins to Agonize MC4R for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4-R for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocortin Receptor 4 (MC4-R or MC4R) - Dormant Projects

Melanocortin Receptor 4 (MC4-R or MC4R) - Discontinued Products

Melanocortin Receptor 4 (MC4-R or MC4R) - Featured News & Press Releases

Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting

Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction

Jan 07, 2016: Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity

Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome

Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction

Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Nov 06, 2015: Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity

Nov 06, 2015: Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity

Oct 13, 2015: Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar Gel to be Unveiled at American College of Rheumatology

Oct 08, 2015: Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar Gel to be Unveiled at American College of Rheumatology

Sep 24, 2015: FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome

Aug 18, 2015: Palatin Technologies Supports FDA's Approval of the First-Ever Treatment for Female Sexual Dysfunction

Jun 04, 2015: Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies

Mar 27, 2015: Positive Outcomes With H.P. Acthar Gel In Proteinuria In Nephrotic Syndrome Reported At National Kidney Foundation Spring Congress

Feb 20, 2015: Palatin Launches Reconnectstudy.Com In Support Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by Mallinckrodt Plc, H1 2016

Pipeline by Obexia AG, H1 2016

Pipeline by Palatin Technologies, Inc., H1 2016

Pipeline by Pfizer Inc., H1 2016

Pipeline by Retrophin Inc., H1 2016

Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • Mallinckrodt Plc
  • Obexia AG
  • Pfizer Inc.
  • Retrophin Inc.
  • MORE
Melanocortin Receptor 4 (MC4-R or MC4R) Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.

Melanocortin Receptor 4 (MC4-R or MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 1 and 6 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Our latest report Melanocortin Receptor 4 (MC4-R or MC4R) – Pipeline Review, H1 2016, outlays comprehensive information on the Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Product cover images may vary from those shown
5 of 6
AstraZeneca Plc
Mallinckrodt Plc
Obexia AG
Palatin Technologies, Inc.
Pfizer Inc.
Retrophin Inc.
Rhythm Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll